Table 1.
Characteristics of patients before PMX-DHP therapy
| Survivors | Non-survivors | p value | |
|---|---|---|---|
| Case No. | 5 | 9 | |
| Age | 64 (36–75) | 58 (44–77) | 0.546 |
| Sex (Male/Female) | 1/4 | 2/7 | 1.000 |
| BMI | 22.1 (20.5–24.1) | 22 (20.6–28.6) | 0.548 |
| Smoking status (Never/Ex/Current) | 4/1/0 | 7/0/2 | 1.000 |
| Days from steroid pulse therapy to PMX-DHP | 5 (1–11) | 6 (1–48) | 0.584 |
| Anti-ARS Ab (PL-7/EJ) Anti-MDA-5 Ab |
3 (2/1) 1 |
0 9 |
0.028* 0.005* |
| IPPV | 1 | 4 | 0.580 |
| Steroid pulse therapy | 5 | 9 | 1.000 |
| Immunosuppressive agents | |||
| Cyclosporine | 4 | 8 | 1.000 |
| Tacrolimus | 1 | 5 | 0.301 |
| Cyclophosphamide pulse | 5 | 9 | 1.000 |
Dates are expressed as group median values or numbers of patients
BMI body mass index, PMX-DHP direct hemoperfusion therapy using a polymyxin B-immobilized fiber column, ARS aminoacyl-tRNA synthetase, PL-7, threonyl; EJ, glycyl; MDA-5 melanoma differentiation-associated gene 5, IPPV invasive positive pressure ventilation
* p value <0.05